Peter Gibson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1968270/publications.pdf

Version: 2024-02-01

317 papers	22,548 citations	8159 76 h-index	9839 141 g-index
322 all docs	322 docs citations	322 times ranked	15595 citing authors

#	Article	IF	Citations
1	Lessons from an audit of exclusive enteral nutrition in adult inpatients and outpatients with active Crohnâ€™s disease: a single-centre experience. Frontline Gastroenterology, 2023, 14, 6-12.	0.9	5
2	Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 136-144.e31.	2.4	21
3	The Reliability and Accuracy of Endoscopic Items and Scores Used in the Assessment of the Ileoanal Pouch and Cuff. Journal of Crohn's and Colitis, 2022, 16, 18-26.	0.6	3
4	Accuracy of Gastrointestinal Ultrasound and Calprotectin in the Assessment of Inflammation and its Location in Patients with an Ileoanal Pouch. Journal of Crohn's and Colitis, 2022, 16, 79-90.	0.6	8
5	Adult sucrase-isomaltase deficiency masquerading as IBS. Gut, 2022, 71, 1237-1238.	6.1	11
6	World Gastroenterology Organisation Global Guidelines. Journal of Clinical Gastroenterology, 2022, 56, 1-15.	1.1	5
7	Diet as a therapeutic tool in chronic gastrointestinal disorders: Lessons from the FODMAP journey. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 644-652.	1.4	11
8	Evaluating tolerability of resistant starch 2, alone and in combination with minimally fermented fibre for patients with irritable bowel syndrome: a pilot randomised controlled cross-over trial. Journal of Nutritional Science, 2022, 11, e15.	0.7	4
9	Cold snare polypectomy of colorectal polyps â‰¥â€Š10â€Šmm on clopidogrel: Australian and New Zealand randomized controlled trial. Endoscopy International Open, 2022, 10, E745-E752.	0.9	1
10	Toward transmural healing: Sonographic healing is associated with improved longâ€term outcomes in patients with Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2022, 56, 84-94.	1.9	17
11	Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2022, 34, 613-621.	0.8	3
12	Self-Worth Beliefs Predict Willingness to Engage in Psychotherapy for Fatigue in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2022, , 1.	1.1	0
13	Supplementing Dietary Fibers With a Low FODMAP Diet in Irritable Bowel Syndrome: A Randomized Controlled Crossover Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 2112-2120.e7.	2.4	15
14	Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Alimentary Pharmacology and Therapeutics, 2022, 55, 700-704.	1.9	17
15	Therapeutic Potential of the 4 Strategies to SUlfide-REduction (4-SURE) Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open-Label Feasibility Study. Journal of Nutrition, 2022, 152, 1690-1701.	1.3	11
16	The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation. American Journal of Gastroenterology, 2022, 117, 947-957.	0.2	31
17	Transcutaneous vagal nerve stimulation protects against stressâ€induced intestinal barrier dysfunction in healthy adults. Neurogastroenterology and Motility, 2022, 34, e14382.	1.6	11
18	Nonspecific ileitis: Impact of histopathology and gastrointestinal ultrasound in achieving the diagnosis of Crohn's disease. JGH Open, 2022, 6, 388-394.	0.7	2

#	Article	IF	Citations
19	Dietary management of adults with IBD â€" the emerging role of dietary therapy. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 652-669.	8.2	40
20	Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppressionâ€"risks, screening, diagnosis and management. Alimentary Pharmacology and Therapeutics, 2022, 56, 6-27.	1.9	17
21	Letter: gutâ€"brain axis dysfunction underlies symptom generation in irritable bowel syndromeâ€"a plea for rational interpretation of irrational doses of <scp>FODMAP</scp> s. Alimentary Pharmacology and Therapeutics, 2022, 56, 366-367.	1.9	2
22	Letter: progressive weakening of the concept that gluten has a detrimental effect on mental health and gut symptoms in the absence of coeliac disease. Alimentary Pharmacology and Therapeutics, 2022, 56, 363-364.	1.9	1
23	Hypermobile Ehlersâ€"Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1693-1709.	1.4	15
24	How to Implement the 3-Phase FODMAP Diet Into Gastroenterological Practice. Journal of Neurogastroenterology and Motility, 2022, 28, 343-356.	0.8	15
25	Coeliac disease in 2022. Alimentary Pharmacology and Therapeutics, 2022, 56, .	1.9	0
26	Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children. Journal of Crohn's and Colitis, 2022, 16, 1835-1844.	0.6	6
27	Dietary Changes Among Breastfeeding Mothers. Journal of Human Lactation, 2021, 37, 566-576.	0.8	2
28	Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome. Gastroenterology, 2021, 160, 47-62.	0.6	81
29	Screening dietary fibres for fermentation characteristics and metabolic profiles using a rapidin vitroapproach: implications for irritable bowel syndrome. British Journal of Nutrition, 2021, 126, 208-218.	1.2	27
30	The Role of Epidemiological Evidence from Prospective Population Studies in Shaping Dietary Approaches to Therapy in Crohn's Disease. Molecular Nutrition and Food Research, 2021, 65, e2000294.	1.5	6
31	Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1580-1589.	1.4	9
32	Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 990-998.	1.4	5
33	Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Selfâ€Reported Nonâ€Coeliac Gluten Sensitivity. Molecular Nutrition and Food Research, 2021, 65, e1901275.	1.5	17
34	Early Assessment With Gastrointestinal Ultrasound in Patients Hospitalised for a Flare of Ulcerative Colitis and Predicting the Need for Salvage Therapy: A Pilot Study. Ultrasound in Medicine and Biology, 2021, 47, 1108-1114.	0.7	14
35	Effect of pointâ€ofâ€care gastrointestinal ultrasound on decisionâ€making and management in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 652-666.	1.9	13
36	Randomised clinical trial: adjunctive induction therapy with oral effervescent budesonide in newly diagnosed coeliac disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 419-428.	1.9	3

#	Article	IF	Citations
37	Naturallyâ€•occurring dietary salicylates in the genesis of functional gastrointestinal symptoms in patients with irritable bowel syndrome: Pilot study. JGH Open, 2021, 5, 871-878.	0.7	4
38	Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 510-510.	1.9	0
39	Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 1280-1287.	0.8	5
40	Microbial Interventions to Control and Reduce Blood Pressure in Australia (MICRoBIA): rationale and design of a double-blinded randomised cross-over placebo controlled trial. Trials, 2021, 22, 496.	0.7	17
41	A systematic review of psychological treatments to manage fatigue in patients with inflammatory bowel disease. Journal of Psychosomatic Research, 2021, 147, 110524.	1.2	8
42	Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine. Gut, 2021, 70, 2383-2394.	6.1	31
43	Anti-TNFÎ± Induction Therapy for Patients With Active Inflammatory Bowel Disease During Pregnancy: A Case Series. Inflammatory Bowel Diseases, 2021, , .	0.9	2
44	Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication. Therapeutic Drug Monitoring, 2021, 43, 692-695.	1.0	1
45	Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis. MDM Policy and Practice, 2021, 6, 23814683209784 1.	0.5	8
46	Delivery of Acetate to the Peripheral Blood after Consumption of Foods High in Shortâ€Chain Fatty Acids. Molecular Nutrition and Food Research, 2021, 65, e2000953.	1.5	13
47	The FODMAP diet: more than just a symptomatic therapy?. Gut, 2021, , gutjnl-2021-326284.	6.1	2
48	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflammatory Bowel Diseases, 2020, 26, 93-102.	0.9	20
49	Imbalance of the reninâ€“angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?. Gut, 2020, 69, 841-851.	6.1	160
50	Successful elevation of circulating acetate and propionate by dietary modulation does not alter T-regulatory cell or cytokine profiles in healthy humans: a pilot study. European Journal of Nutrition, 2020, 59, 2651-2661.	1.8	20
51	Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 465-479.	0.6	52
52	Commentary: recognising the boom in coeliac disease prevalence was more than just increased awareness. Alimentary Pharmacology and Therapeutics, 2020, 51, 207-208.	1.9	1
53	Chronic constipation and abdominal pain: Independent or closely interrelated symptoms?. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1294-1301.	1.4	18
54	Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohnâ€™s Disease than Endoscopic Healing. Clinical Gastroenterology and Hepatology, 2020, 18, 2518-2525.e1.	2.4	64

#	Article	IF	Citations
55	FODMAPs and carbohydrate intolerance. , 2020, , 371-386.		3
56	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 2020, 52, 1551-1562.	1.9	38
57	Nutritional profile of rodent diets impacts experimental reproducibility in microbiome preclinical research. Scientific Reports, 2020, 10, 17784.	1.6	24
58	Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1174-1184.	1.9	20
59	Review article: FODMAPS, prebiotics and gut healthâ€the FODMAP hypothesis revisited. Alimentary Pharmacology and Therapeutics, 2020, 52, 233-246.	1.9	75
60	Randomised clinical trial: transabdominal interferential electrical stimulation vs sham stimulation in women with functional constipation. Alimentary Pharmacology and Therapeutics, 2020, 51, 760-769.	1.9	18
61	The Potential of Integrated Nurse-Led Models to Improve Care for People With Functional Gastrointestinal Disorders. Gastroenterology Nursing, 2020, 43, 53-64.	0.2	10
62	Initial experiences of an inâ€reach service providing iron infusions in residential aged care facilities. Australasian Journal on Ageing, 2020, 39, e454-e459.	0.4	1
63	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1381-1392.	2.4	161
64	Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 612-628.	1.9	49
65	The Importance of Accurate Phenotyping and Pouchitis Risk and Dietary Assessment When Investigating the Microbial Factors Behind Antibiotic-Dependent Pouchitis. Gastroenterology, 2020, 159, 399-400.	0.6	1
66	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. Journal of Crohn's and Colitis, 2020, 14, 1345-1353.	0.6	9
67	Editorial: inaccuracies in attribution of symptoms due to glutenâ€"not just in those with selfâ€reported noncoeliac gluten sensitivity. Alimentary Pharmacology and Therapeutics, 2020, 51, 402-403.	1.9	4
68	Dietary fat and the faecal microbiome: where collinearity may lead to incorrect attribution of effects to fat. Gut, 2020, 69, 1718.2-1718.	6.1	12
69	Review article: the impact of diet on ileoanal pouch function and on the pathogenesis of pouchitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1323-1340.	1.9	11
70	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflammatory Bowel Diseases, 2019, 25, 163-171.	0.9	6
71	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 486-493.	2.4	76
72	Review article: the role of the autonomic nervous system in the pathogenesis and therapy of IBD. Alimentary Pharmacology and Therapeutics, 2019, 50, 720-737.	1.9	45

#	Article	IF	Citations
73	Sa2038 â€“ Lack of Experimental Reproducibility in Preclinical Research May Be Influenced by the Nutritional Profile of Standard Rodent Chows. Gastroenterology, 2019, 156, S-481.	0.6	1
74	Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 733-747.	8.2	116
75	The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481882256.	1.4	31
76	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1462-1473.	0.9	15
77	Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. Journal of Crohn's and Colitis, 2019, 13, 1527-1536.	0.6	2
78	Letters: low FODMAP dietâ€"directions for future research and the low FODMAP diet is not the only diet for IBSâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1109-1110.	1.9	0
79	Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1134-1142.	1.4	72
80	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 573-574.	2.4	0
81	Study design of endoscopic polypectomy on clopidogrel (EPOC): A randomised controlled trial. Contemporary Clinical Trials Communications, 2019, 16, 100479.	0.5	1
82	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohnâ€™s Disease. Digestive Diseases and Sciences, 2019, 64, 1622-1631.	1.1	8
83	Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndromeâ€"directions for future research. Alimentary Pharmacology and Therapeutics, 2019, 49, 124-139.	1.9	56
84	Prebiotics Versus Low FODMAP Diet: An Interpretative Nightmare. Gastroenterology, 2019, 156, 1222.	0.6	1
85	Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS ONE, 2019, 14, e0210728.	1.1	109
86	Gluten-free and low-FODMAP sourdoughs for patients with coeliac disease and irritable bowel syndrome: A clinical perspective. International Journal of Food Microbiology, 2019, 290, 237-246.	2.1	44
87	AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 380-390.e1.	2.4	104
88	Review article: emulsifiers in the food supply and implications for gastrointestinal disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 41-50.	1.9	63
89	Efficacy of glutamine in postinfection IBS. Gut, 2019, 68, 1905-1906.	6.1	4
90	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (<scp>AAA</scp> Study). Alimentary Pharmacology and Therapeutics, 2018, 47, 1092-1102.	1.9	38

#	Article	IF	Citations
91	Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. Journal of Crohn's and Colitis, 2018, 12, 289-297.	0.6	39
92	Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1423-1424.	1.9	5
93	Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut, 2018, 67, 973-985.	6.1	116
94	Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 753-762.	1.9	63
95	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 653-661.	0.6	22
96	The Impact of Mild Heat Stress During Prolonged Running On Gastrointestinal Integrity, Gastrointestinal Symptoms, Systemic Endotoxin and Cytokine Profiles. International Journal of Sports Medicine, 2018, 39, 255-263.	0.8	56
97	Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 10-11.	1.4	3
98	A human pilot trial of ingestible electronic capsules capable of sensing different gases in the gut. Nature Electronics, 2018, 1, 79-87.	13.1	240
99	The impact of exertional-heat stress on gastrointestinal integrity, gastrointestinal symptoms, systemic endotoxin and cytokine profile. European Journal of Applied Physiology, 2018, 118, 389-400.	1.2	97
100	Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Alimentary Pharmacology and Therapeutics, 2018, 48, 15-34.	1.9	339
101	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflammatory Bowel Diseases, 2018, 24, 849-860.	0.9	34
102	Modulation of colonic hydrogen sulfide production by diet and mesalazine utilizing a novel gas-profiling technology. Gut Microbes, 2018, 9, 1-13.	4.3	23
103	Reducing the maternal dietary intake of indigestible and slowly absorbed shortâ€chain carbohydrates is associated with improved infantile colic: a proofâ€ofâ€concept study. Journal of Human Nutrition and Dietetics, 2018, 31, 256-265.	1.3	16
104	Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease. Clinical Nutrition, 2018, 37, 1375-1382.	2.3	42
105	Two weeks of repetitive gutâ€challenge reduce exerciseâ€associated gastrointestinal symptoms and malabsorption. Scandinavian Journal of Medicine and Science in Sports, 2018, 28, 630-640.	1.3	50
106	Dietary practices and FODMAPs in South Asia: Applicability of the low FODMAP diet to patients with irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 365-374.	1.4	25
107	Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 280-288.	0.6	20
108	Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by Î±-Galactosidase Treatment. American Journal of Gastroenterology, 2018, 113, 124-134.	0.2	40

#	Article	IF	Citations
109	Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity. Gastroenterology, 2018, 154, 529-539.e2.	0.6	317
110	Performance of an algorithmâ€based approach to the diagnosis and management of functional gastrointestinal disorders: A pilot trial. Neurogastroenterology and Motility, 2018, 30, e13243.	1.6	7
111	Inaccuracy of patientâ€reported descriptions of and satisfaction with bowel actions in irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13187.	1.6	22
112	Characterization of ulcerative colitisâ€associated constipation syndrome (proximal constipation). JGH Open, 2018, 2, 217-222.	0.7	12
113	Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 2018, 48, 1328-1330.	1.9	14
114	Randomised clinical trial: reducing the intake of dietary <scp>FODMAP</scp>s of breastfeeding mothers is associated with a greater improvement of the symptoms of infantile colic than for a typical diet. Alimentary Pharmacology and Therapeutics, 2018, 48, 1061-1073.	1.9	26
115	Illuminating dark depths. Science, 2018, 360, 856-857.	6.0	8
116	Neuromodulation via Interferential Electrical Stimulation as a Novel Therapy in Gastrointestinal Motility Disorders. Journal of Neurogastroenterology and Motility, 2018, 24, 19-29.	0.8	33
117	Culture- and metagenomics-enabled analyses of the Methanosphaera genus reveals their monophyletic origin and differentiation according to genome size. ISME Journal, 2018, 12, 2942-2953.	4.4	24
118	The safety and sensitivity of a telemetric capsule to monitor gastrointestinal hydrogen production inÂvivo in healthy subjects: a pilot trial comparison to concurrent breath analysis. Alimentary Pharmacology and Therapeutics, 2018, 48, 646-654.	1.9	46
119	Genome mapping of seed-borne allergens and immunoresponsive proteins in wheat. Science Advances, 2018, 4, eaar8602.	4.7	130
120	Is Non-Celiac Rice-Starch Sensitivity as Common in Children as Non-Celiac Gluten Sensitivity?. American Journal of Gastroenterology, 2018, 113, 1254.	0.2	4
121	Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. Journal of Crohn's and Colitis, 2018, 12, 1053-1066.	0.6	17
122	Naturally occurring dietary salicylates: A closer look at common Australian foods. Journal of Food Composition and Analysis, 2017, 57, 31-39.	1.9	22
123	Gut-training: the impact of two weeks repetitive gut-challenge during exercise on gastrointestinal status, glucose availability, fuel kinetics, and running performance. Applied Physiology, Nutrition and Metabolism, 2017, 42, 547-557.	0.9	106
124	Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clinical Gastroenterology and Hepatology, 2017, 15, 1557-1564.e1.	2.4	157
125	History of the low FODMAP diet. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 5-7.	1.4	59
126	Use of the lowâ€FODMAP diet in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 40-42.	1.4	85

#	Article	IF	Citations
127	Nonâ€coeliac gluten sensitivity. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 86-89.	1.4	37
128	Intraâ€patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1135-1145.	1.9	40
129	The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a firstâ€line therapy?. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 32-35.	1.4	46
130	FODMAPs: food composition, defining cutoff values and international application. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 53-61.	1.4	146
131	Editorial: rethinking predictors of response to the low FODMAP diet â€“ should we retire fructose and lactose breathâ€hydrogen testing and concentrate on visceral hypersensitivity?. Alimentary Pharmacology and Therapeutics, 2017, 45, 1281-1282.	1.9	8
132	Editorial: variability in adalimumab trough and peak serum concentrations â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1476-1477.	1.9	0
133	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Alimentary Pharmacology and Therapeutics, 2017, 46, 150-161.	1.9	53
134	Systematic review: exerciseâ€induced gastrointestinal syndromeâ€”implications for health and intestinal disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 246-265.	1.9	258
135	Undiagnosed pancreatic exocrine insufficiency and chronic pancreatitis in functional GI disorder patients with diarrhea or abdominal pain. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1813-1817.	1.4	19
136	Poor reproducibility of breath hydrogen testing: Implications for its application in functional bowel disorders. United European Gastroenterology Journal, 2017, 5, 284-292.	1.6	39
137	Endometriosis in patients with irritable bowel syndrome: Specific symptomatic and demographic profile, and response to the low FODMAP diet. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 201-205.	0.4	63
138	Letter: lowâ€<scp>FODMAP</scp> diet for exerciseâ€induced gastrointestinal syndromeâ€”Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 1023-1024.	1.9	4
139	Easing Concerns About the Low FODMAP Diet in Patients With Irritable Bowel Syndrome. Gastroenterology, 2017, 153, 886-887.	0.6	7
140	Letter: bias in clinical trials of the symptomatic effects of the low <scp>FODMAP</scp> diet for irritable bowel syndromeâ€”getting the facts right. Alimentary Pharmacology and Therapeutics, 2017, 46, 385-386.	1.9	4
141	Carbohydrate and protein intake during exertional heat stress ameliorates intestinal epithelial injury and small intestine permeability. Applied Physiology, Nutrition and Metabolism, 2017, 42, 1283-1292.	0.9	76
142	Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population. Therapeutic Advances in Gastroenterology, 2017, 10, 74-88.	1.4	23
143	Complementary and Alternative Medicines Used by Patients WithÂInflammatory Bowel Diseases. Gastroenterology, 2017, 152, 415-429.e15.	0.6	114
144	Challenges of Quantifying FODMAPs in Enteral Nutrition Formulas: Evaluation of Artifacts and Solutions. Journal of Parenteral and Enteral Nutrition, 2017, 41, 1262-1271.	1.3	10

#	Article	IF	Citations
145	Designing an in-vitro gas profiling system for human faecal samples. Sensors and Actuators B: Chemical, 2017, 238, 754-764.	4.0	13
146	Adding glucose to food and solutions to enhance fructose absorption is not effective in preventing fructoseâ€induced functional gastrointestinal symptoms: randomised controlled trials in patients with fructose malabsorption. Journal of Human Nutrition and Dietetics, 2017, 30, 73-82.	1.3	20
147	Referrals to a tertiary hospital: A window into clinical management issues in functional gastrointestinal disorders. JGH Open, 2017, 1, 84-91.	0.7	13
148	White Diet with splitâ€dose Picosalax is preferred, better tolerated, and nonâ€inferior to dayâ€before clear fluids with polyethylene glycol plus sodium picosulfateâ€magnesium citrate for morning colonoscopy: A randomized, nonâ€inferiority trial. JGH Open, 2017, 1, 38-43.	0.7	8
149	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. World Journal of Gastroenterology, 2017, 23, 6385-6402.	1.4	51
150	Controversies and Recent Developments of the Low-FODMAP Diet. Gastroenterology and Hepatology, 2017, 13, 36-45.	0.2	38
151	Adherence to the glutenâ€free diet can achieve the therapeutic goals in almost all patients with coeliac disease: A 5â€year longitudinal study from diagnosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 342-349.	1.4	55
152	Safety of rapid infusion of iron polymaltose: comparative study in 300 patients. Journal of Pharmacy Practice and Research, 2016, 46, 324-330.	0.5	3
153	Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn's Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. Clinical and Translational Gastroenterology, 2016, 7, e164.	1.3	170
154	Concentrations of Adalimumab and Infliximab in Mothers andÂNewborns, and Effects on Infection. Gastroenterology, 2016, 151, 110-119.	0.6	259
155	Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clinical and Translational Gastroenterology, 2016, 7, e168.	1.3	34
156	Editorial: management of eosinophilic oesophagitis â€“ efficacy vs. effectiveness. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 199-200.	1.9	0
157	Review article: insights into colonic protein fermentation, its modulation and potential health implications. Alimentary Pharmacology and Therapeutics, 2016, 43, 181-196.	1.9	305
158	Randomised clinical trial: the efficacy of gutâ€directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2016, 44, 447-459.	1.9	107
159	Editorial: gutâ€directed hypnotherapy or low <scp>FODMAP</scp> diet for the treatment of irritable bowel syndrome? Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 902-903.	1.9	1
160	Uncertain Diagnostic Language Affects Further Studies, Endoscopies, and Repeat Consultations for Patients WithÂFunctional Gastrointestinal Disorders. Clinical Gastroenterology and Hepatology, 2016, 14, 1735-1741.e1.	2.4	22
161	Potential of in vivo real-time gastric gas profiling: a pilot evaluation of heat-stress and modulating dietary cinnamon effect in an animal model. Scientific Reports, 2016, 6, 33387.	1.6	29
162	Letter: avoiding misconceptions about elimination diet for eosinophilic oesophagitis â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 100-101.	1.9	0

#	Article	IF	Citations
163	Letter: dietary therapy in eosinophilic oesophagitis â€“ do not test, just eliminate and reintroduce the most common food triggers. Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 905-906.	1.9	1
164	The White Diet is preferred, better tolerated, and nonâ€inferior to a clearâ€fluid diet for bowel preparation: A randomized controlled trial. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 355-363.	1.4	26
165	<scp>A</scp>sia <scp>P</scp>acific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 45-55.	1.4	92
166	The Crohn's Diseaseâ€“Ulcerative Colitis Clinical Appraisal. Clinical Gastroenterology and Hepatology, 2016, 14, 638-639.	2.4	1
167	Diet Therapy for Irritable Bowel Syndrome: Is a Diet Low in FODMAPS Really Similar in Efficacy to Traditional Dietary Advice?. Gastroenterology, 2016, 150, 1046-1047.	0.6	8
168	The Lactulose Breath Test in Irritable Bowel Syndrome: Is It All Hot Air?. Digestive Diseases and Sciences, 2016, 61, 655-657.	1.1	6
169	Intestinal Gas Capsules: A Proof-of-Concept Demonstration. Gastroenterology, 2016, 150, 37-39.	0.6	56
170	<scp>A</scp>siaâ€“<scp>P</scp>acific consensus statements on <scp>C</scp>rohn's disease. Part 2: Management. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 56-68.	1.4	42
171	Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?. Gut, 2016, 65, 169-178.	6.1	154
172	B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy. PLoS ONE, 2016, 11, e0160103.	1.1	49
173	Randomised clinical trial: a placeboâ€controlled study of intravenous golimumab induction therapy for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2015, 42, 504-514.	1.9	63
174	Editorial: predicting response to a low FODMAP diet in children. Alimentary Pharmacology and Therapeutics, 2015, 42, 775-776.	1.9	1
175	Editorial: noncoeliac gluten sensitivity - the controversy rages on. Alimentary Pharmacology and Therapeutics, 2015, 42, 1234-1234.	1.9	2
176	How healthy is a gluten-free diet?. British Journal of Nutrition, 2015, 114, 1539-1541.	1.2	28
177	Long-term outcomes of colectomy surgery among patients with ulcerative colitis. SpringerPlus, 2015, 4, 573.	1.2	34
178	Seasonal recurrence of food bolus obstruction in eosinophilic esophagitis. Internal Medicine Journal, 2015, 45, 939-943.	0.5	36
179	Poor predictive value of breath hydrogen response for probiotic effects in IBS. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1731-1739.	1.4	10
180	Review article: gutâ€directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 1104-1115.	1.9	87

#	Article	IF	Citations
181	The Low FODMAP Diet and Its Application in East and Southeast Asia. Journal of Neurogastroenterology and Motility, 2015, 21, 459-470.	0.8	58
182	Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome. World Journal of Gastroenterology, 2015, 21, 11379.	1.4	6
183	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 452-462.	0.6	30
184	Human intestinal gas measurement systems: in vitro fermentation and gas capsules. Trends in Biotechnology, 2015, 33, 208-213.	4.9	102
185	Crohn's disease management after intestinal resection: a randomised trial. Lancet, The, 2015, 385, 1406-1417.	6.3	475
186	Food Components and Irritable Bowel Syndrome. Gastroenterology, 2015, 148, 1158-1174.e4.	0.6	173
187	Dietary management of IBDâ€"insights and advice. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 133-146.	8.2	71
188	IgG and EoE: Too Soon for a Paradigm Shift Away From IgE. Gastroenterology, 2015, 148, 453-454.	0.6	7
189	Abnormal fibre usage in UC in remission. Gut, 2015, 64, 562-570.	6.1	89
190	Metabolomics as a tool for diagnosis and monitoring in coeliac disease. Metabolomics, 2015, 11, 980-990.	1.4	12
191	Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery. Gastroenterology, 2015, 148, 938-947.e1.	0.6	241
192	Other Dietary Confounders: FODMAPS et al.. Digestive Diseases, 2015, 33, 269-276.	0.8	34
193	Practical insights into gluten-free diets. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 580-591.	8.2	119
194	Editorial: a new shift in the paradigm of treatment for the irritable bowel syndrome?. Alimentary Pharmacology and Therapeutics, 2015, 41, 1296-1296.	1.9	0
195	What Gastroenterologists Should Know About Testing Patients With Eosinophilic Esophagitis for Food Allergies. Clinical Gastroenterology and Hepatology, 2015, 13, 1029-1030.	2.4	1
196	Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 559-569.	1.0	70
197	Eosinophilic esophagitis: A clinicopathological review. , 2015, 146, 12-22.		21
198	Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut, 2015, 64, 93-100.	6.1	552

#	Article	IF	Citations
199	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut, 2014, 63, 433-441.	6.1	222
200	Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. Frontline Gastroenterology, 2014, 5, 183-189.	0.9	16
201	Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome. Journal of Human Nutrition and Dietetics, 2014, 27, 263-275.	1.3	96
202	Cognitive impairment in coeliac disease improves on a glutenâ€free diet and correlates with histological and serological indices of disease severity. Alimentary Pharmacology and Therapeutics, 2014, 40, 160-170.	1.9	69
203	Commentary: broadening the focus of coeliac management to follow-up strategies. Alimentary Pharmacology and Therapeutics, 2014, 39, 112-112.	1.9	0
204	Drug-induced gastrointestinal disorders. Frontline Gastroenterology, 2014, 5, 49-57.	0.9	38
205	Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2014, 8, 819-834.	1.4	99
206	Delving into disability in Crohn's disease: Dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 626-634.	0.6	59
207	Reply. Gastroenterology, 2014, 146, 1830-1831.	0.6	4
208	Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. Journal of Crohn's and Colitis, 2014, 8, 598-606.	0.6	95
209	Randomised clinical trial: gluten may cause depression in subjects with nonâ€coeliac gluten sensitivity â€“ an exploratory clinical study. Alimentary Pharmacology and Therapeutics, 2014, 39, 1104-1112.	1.9	100
210	Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 535-540.	1.1	217
211	Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2014, 146, 96-109.e1.	0.6	605
212	A Diet Low in FODMAPs Reduces Symptoms of Irritable BowelÂSyndrome. Gastroenterology, 2014, 146, 67-75.e5.	0.6	989
213	Characterization of Adults With a Selfâ€Diagnosis of Nonceliac Gluten Sensitivity. Nutrition in Clinical Practice, 2014, 29, 504-509.	1.1	85
214	Republished: Drug-induced gastrointestinal disorders. Postgraduate Medical Journal, 2014, 90, 411-419.	0.9	31
215	Reply. Gastroenterology, 2014, 146, 321-322.	0.6	1
216	Objectively measured muscle fatigue in Crohn's disease: Correlation with self-reported fatigue and associated factors for clinical application. Journal of Crohn's and Colitis, 2014, 8, 137-146.	0.6	50

#	Article	IF	Citations
217	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2014, 146, 85-95.	0.6	753
218	No Effects of Gluten in Patients With Self-Reported Non-Celiac Gluten Sensitivity After Dietary Reduction of Fermentable, Poorly Absorbed, Short-Chain Carbohydrates. Gastroenterology, 2013, 145, 320-328.e3.	0.6	676
219	Not All Effects of a Gluten-Free Diet Are Due to Removal of Gluten. Gastroenterology, 2013, 145, 693.	0.6	18
220	Is Gluten a Cause of Gastrointestinal Symptoms in People Without Celiac Disease?. Current Allergy and Asthma Reports, 2013, 13, 631-638.	2.4	56
221	Alternative investigations for irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 73-77.	1.4	11
222	Short-Chain Carbohydrates and Functional Gastrointestinal Disorders. American Journal of Gastroenterology, 2013, 108, 707-717.	0.2	218
223	Design of Clinical Trials Evaluating Dietary Interventions in Patients With Functional Gastrointestinal Disorders. American Journal of Gastroenterology, 2013, 108, 748-758.	0.2	99
224	Association of Circulating Vitamin D Concentrations with Intestinal but Not Systemic Inflammation in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2634-2643.	0.9	87
225	Fructose malabsorption syndrome. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 1.	1.3	31
226	Semiquantitative assessment of breath hydrogen testing. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1450-1456.	1.4	4
227	Nonâ€nutritional effects of food: An underutilized and understudied therapeutic tool in chronic gastrointestinal diseases. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 37-40.	1.4	10
228	Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in <scp>A</scp>ustralians deployed abroad. Internal Medicine Journal, 2013, 43, 919-926.	0.5	20
229	Letter: oral fructose - breath hydrogen response, symptoms, both or neither?. Alimentary Pharmacology and Therapeutics, 2013, 38, 442-443.	1.9	4
230	Nutritional inadequacies of the glutenâ€free diet in both recentlyâ€diagnosed and longâ€term patients with coeliac disease. Journal of Human Nutrition and Dietetics, 2013, 26, 349-358.	1.3	217
231	Commentary: sugar intolerances in functional gastrointestinal disorders. Alimentary Pharmacology and Therapeutics, 2013, 38, 72-72.	1.9	2
232	Functional bowel symptoms and diet. Internal Medicine Journal, 2013, 43, 1067-1074.	0.5	34
233	Venous and arterial disease in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1095-1113.	1.4	61
234	The Low FODMAP Diet for Treatment of Irritable Bowel Syndrome and Other Gastrointestinal Disorders. Gastroenterology and Hepatology, 2013, 9, 450-2.	0.2	12

#	Article	IF	Citations
235	Systemic mastocytosis: a gastroenterological perspective. Frontline Gastroenterology, 2012, 3, 5-9.	0.9	4
236	Food Choice as a Key Management Strategy for Functional Gastrointestinal Symptoms. American Journal of Gastroenterology, 2012, 107, 657-666.	0.2	156
237	Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study. Internal Medicine Journal, 2012, 42, 907-912.	0.5	6
238	Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?. Therapeutic Advances in Gastroenterology, 2012, 5, 261-268.	1.4	130
239	For Celiac Disease, Diagnosis Is Not Enough. Clinical Gastroenterology and Hepatology, 2012, 10, 900-901.	2.4	11
240	Review article: the pathophysiological roles of the reninâ€“angiotensin system in the gastrointestinal tract. Alimentary Pharmacology and Therapeutics, 2012, 35, 414-428.	1.9	123
241	Review article: vitamin <scp>D</scp> and inflammatory bowel disease â€“ established concepts and future directions. Alimentary Pharmacology and Therapeutics, 2012, 36, 324-344.	1.9	91
242	Gluten Causes Gastrointestinal Symptoms in Subjects Without Celiac Disease: A Double-Blind Randomized Placebo-Controlled Trial. American Journal of Gastroenterology, 2011, 106, 508-514.	0.2	606
243	Food intolerance in functional bowel disorders. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 128-131.	1.4	60
244	Quantification of fructans, galacto-oligosacharides and other short-chain carbohydrates in processed grains and cereals. Journal of Human Nutrition and Dietetics, 2011, 24, 154-176.	1.3	274
245	Benefits of breath hydrogen testing after lactulose administration in analysing carbohydrate malabsorption. European Journal of Gastroenterology and Hepatology, 2010, 22, 318-326.	0.8	58
246	The concept of small intestinal bacterial overgrowth in relation to functional gastrointestinal disorders. Nutrition, 2010, 26, 1038-1043.	1.1	32
247	Development and Validation of a Comprehensive Semi-Quantitative Food Frequency Questionnaire that Includes FODMAP Intake and Glycemic Index. Journal of the American Dietetic Association, 2010, 110, 1469-1476.	1.3	99
248	Dietary poorly absorbed, shortâ€chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Alimentary Pharmacology and Therapeutics, 2010, 31, 874-882.	1.9	295
249	Systematic review: fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2010, 32, 131-143.	1.9	171
250	Diarrhoea during enteral nutrition is predicted by the poorly absorbed shortâ€chain carbohydrate (FODMAP) content of the formula. Alimentary Pharmacology and Therapeutics, 2010, 32, 925-933.	1.9	53
251	Evidenceâ€based dietary management of functional gastrointestinal symptoms: The FODMAP approach. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 252-258.	1.4	489
252	Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1366-1373.	1.4	476

#	Article	IF	Citations
253	Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. Alimentary Pharmacology and Therapeutics, 2009, 30, 165-174.	1.9	131
254	Overview of inflammatory bowel disease in Australia in the last 50â€ƒyears. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, S63-8.	1.4	6
255	Strategies to Manage Gastrointestinal Symptoms Complicating Enteral Feeding. Journal of Parenteral and Enteral Nutrition, 2009, 33, 21-26.	1.3	40
256	Measurement of Short-Chain Carbohydrates in Common Australian Vegetables and Fruits by High-Performance Liquid Chromatography (HPLC). Journal of Agricultural and Food Chemistry, 2009, 57, 554-565.	2.4	292
257	Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel diseaseâ€”a pilot study. Journal of Crohn's and Colitis, 2009, 3, 8-14.	0.6	256
258	A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: A case for subcutaneous administration. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 954-958.	1.4	41
259	Systematic review: the evidence base for longâ€term management of coeliac disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 1042-1066.	1.9	177
260	Dietary Triggers of Abdominal Symptoms in Patients With Irritable Bowel Syndrome: Randomized Placebo-Controlled Evidence. Clinical Gastroenterology and Hepatology, 2008, 6, 765-771.	2.4	477
261	Apoptosis or Necrosis-Colonic Epithelial Cell Survival. Novartis Foundation Symposium, 2008, , 133-150.	1.2	10
262	Review article: fructose malabsorption and the bigger picture. Alimentary Pharmacology and Therapeutics, 2007, 25, 349-363.	1.9	208
263	Fructan and Free Fructose Content of Common Australian Vegetables and Fruit. Journal of Agricultural and Food Chemistry, 2007, 55, 6619-6627.	2.4	237
264	Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon. Inflammatory Bowel Diseases, 2007, 13, 1522-1528.	0.9	80
265	Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1306-1312.	1.4	53
266	Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy?. Alimentary Pharmacology and Therapeutics, 2007, 26, 1019-1024.	1.9	71
267	Does butyrate protect from colorectal cancer?. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 209-218.	1.4	171
268	Understanding the gluten-free diet for teaching in Australia. Nutrition and Dietetics, 2006, 63, 155-165.	0.9	11
269	Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 1017-1026.	1.9	43
270	Fructose Malabsorption and Symptoms of Irritable Bowel Syndrome: Guidelines for Effective Dietary Management. Journal of the American Dietetic Association, 2006, 106, 1631-1639.	1.3	356

#	Article	IF	Citations
271	Personal view: food for thought - western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Alimentary Pharmacology and Therapeutics, 2005, 21, 1399-1409.	1.9	295
272	The Influence of Specific Luminal Factors on the Colonic Epithelium: High-Dose Butyrate and Physical Changes Suppress Early Carcinogenic Events in Rats. Diseases of the Colon and Rectum, 2005, 48, 549-559.	0.7	28
273	Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?. Gut, 2005, 54, 900-903.	6.1	37
274	Increased gut permeability in Crohn's disease: is TNF the link?. Gut, 2004, 53, 1724-1725.	6.1	123
275	Apoptosis or necrosis--colonic epithelial cell survival. Novartis Foundation Symposium, 2004, 263, 133-45; discussion 145-50, 211-8.	1.2	1
276	Dietary fibre: a roughage guide. Internal Medicine Journal, 2003, 33, 291-296.	0.5	80
277	Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology, 2001, 120, 889-899.	0.6	108
278	Short-chain fatty acids reduce expression of specific protein kinase C isoforms in human colonic epithelial cells. , 2000, 182, 222-231.		17
279	Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation. Journal of Cellular Physiology, 2000, 183, 347-354.	2.0	87
280	THE HOST INFLAMMATORY RESPONSE TO HELICOBACTER PYLORI. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, H24-H25.	1.4	0
281	GERD AND H. PYLORI INFECTION. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, H22-H22.	1.4	0
282	Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: a study in pigs. Gut, 1999, 45, 840-847.	6.1	147
283	Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis, 1999, 20, 539-544.	1.3	78
284	Effect of butyrate on paracellular permeability in rat distal colonic mucosaex vivo. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 873-879.	1.4	48
285	Relationship of hydrolase activities to epithelial cell turnover in distal colonic mucosa of normal rats. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 866-872.	1.4	11
286	Interleukin-8 stimulates the migration of human colonic epithelial cells in vitro. Clinical Science, 1999, 97, 385-390.	1.8	59
287	Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover. Gut, 1998, 43, 656-663.	6.1	15
288	Effect of Topical Butyrate on Rectal Epithelial Kinetics and Mucosal Enzyme Activities. Clinical Science, 1998, 94, 671-676.	1.8	16

#	Article	IF	Citations
289	Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. Gastroenterology, 1997, 113, 487-496.	0.6	90
290	Wheat bran suppresses potato starch--potentiated colorectal tumorigenesis at the aberrant crypt stage in a rat model. Gastroenterology, 1996, 110, 508-514.	0.6	118
291	Protective Role of the Epithelium of the Small Intestine and Colon. Inflammatory Bowel Diseases, 1996, 2, 279-302.	0.9	28
292	A comparison of Doppler flowmetry with conventional assessment of acute changes in hepatic blood flow. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 14-20.	1.4	6
293	Measurement of faecal Î±₁â€antitrypsin: Methodologies and clinical application. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 311-318.	1.4	3
294	Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis. Inflammatory Bowel Diseases, 1996, 2, 105-114.	0.9	10
295	Protective role of the epithelium of the small intestine and colon. Inflammatory Bowel Diseases, 1996, 2, 279-302.	0.9	25
296	Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis. Inflammatory Bowel Diseases, 1996, 2, 105-14.	0.9	2
297	Protective role of the epithelium of the small intestine and colon. Inflammatory Bowel Diseases, 1996, 2, 279-302.	0.9	15
298	Dietary modulation of colonic mucosal urokinase activity in rats. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 324-330.	1.4	5
299	Lower gastrointestinal tract*: 2. Diarrhoea and diverticular disease. Medical Journal of Australia, 1995, 162, 217-219.	0.8	0
300	Tacrine-Induced Hepatotoxicity. CNS Drugs, 1995, 4, 168-181.	2.7	26
301	Lower gastrointestinal tract. Medical Journal of Australia, 1995, 162, 155-157.	0.8	3
302	Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro. Gastroenterology, 1994, 107, 410-419.	0.6	29
303	Butyrate production from dietary fibre and protection against large bowel cancer in a rat model.. Gut, 1993, 34, 386-391.	6.1	484
304	Percutaneous transhepatic measurement of the pressure gradient between the portal and hepatic veins. Australian and New Zealand Journal of Medicine, 1993, 23, 374-380.	0.5	2
305	Contrasting effects of butyrate on the expression of phenotypic markers of differentiation in neoplastic and non-neoplastic colonic epithelial cells in vitro. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 165-172.	1.4	69
306	A comparison of duplex Doppler sonography of the ligamentum teres and portal vein with endoscopic demonstration of gastroesophageal varices in patients with chronic liver disease or portal hypertension, or both. Journal of Ultrasound in Medicine, 1992, 11, 327-331.	0.8	4

#	Article	IF	Citations
307	Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology, 1992, 15, 1054-1059.	3.6	71
308	Augmentinâ€induced jaundice with a fatal outcome. Medical Journal of Australia, 1992, 156, 285-286.	0.8	39
309	Duplex Doppler ultrasound of the ligamentum teres and portal vein: A clinically useful adjunct in the evaluation of patients with known or suspected chronic liver disease or portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 61-65.	1.4	10
310	Different fibers have different regional effects on luminal contents of rat colon. Gastroenterology, 1991, 101, 1274-1281.	0.6	132
311	Cell associated urokinase activity and colonic epithelial cells in health and disease.. Gut, 1991, 32, 191-195.	6.1	11
312	Splenomegalyâ€”an insensitive sign of portal hypertension. Australian and New Zealand Journal of Medicine, 1990, 20, 771-774.	0.5	40
313	Current concepts in the pathogenesis of Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 44-65.	1.4	8
314	PATHOPHYSIOLOGY OF PORTAL HYPERTENSION AND IMPLICATIONS FOR ITS PHARMACOLOGICAL CONTROL. Australian and New Zealand Journal of Medicine, 1989, 19, 172-182.	0.5	5
315	Correspondence. Hepatology, 1988, 8, 1723-1723.	3.6	2
316	Serum enzyme pattern in acute liver disease: Relation to type of cell death. Journal of Gastroenterology and Hepatology (Australia), 1987, 2, 419-422.	1.4	0
317	The hypotensive effect of oral nitroglycerin on portal venous pressure in patients with cirrhotic portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 1986, 1, 201-206.	1.4	17